Loading...
Defines medical necessity criteria, limitations, and non-coverage determinations for various nerve block and neurolytic procedures (occipital, sympathetic, celiac plexus, intercostal, genicular, peripheral/ganglion, intraosseous basivertebral nerve ablation) for non‑Medicare Centene-affiliated plans; includes related coding implications.
Added note directing sacroiliac and facet joint interventions to CP.MP.166 and CP.MP.171, respectively, and Medicare plans to MC.CP.MP.170.
Added clarifying verbiage regarding non-Medicare health plans in Policy/Criteria with no impact to criteria.
Updated Criteria II.A.1.c to include topical application of lidocaine.
Added refractory chronic pancreatitis as a medically necessary indication for celiac plexus block.
Added CPT code 64628 (thermal destruction of intraosseous basivertebral nerve).
This policy (Policy Number CP.MP.170, effective date 2025-02-01) defines medical necessity criteria, limits, and non-coverage determinations for a range of nerve block and neurolytic procedures. The coverage stance is mixed: some procedures are supported and covered when specific criteria are met, while others are deemed not medically necessary or have insufficient evidence. Indications addressed include occipital nerve blocks, sympathetic blocks (including for CRPS), celiac plexus block/neurolysis (pancreatic cancer and refractory chronic pancreatitis), intercostal nerve block/neurolysis, genicular interventions, various peripheral/ganglion nerve blocks (including post-herniorrhaphy and malignant pain), and intraosseous basivertebral nerve ablation (Intracept).
Occipital Nerve Block - Not Medically Necessary
Sympathetic Nerve Blocks - Not Medically Necessary
Celiac Plexus Nerve Block/Neurolysis - Not Medically Necessary
Genicular Nerve Blocks/Neurolysis/Radiofrequency Neurotomy - Policy statement about insufficient evidence
Policy statement
Peripheral/Ganglion Nerve Blocks - Malignant Pain
Covered as part of a comprehensive program:
Peripheral/Ganglion Nerve Blocks - Not Medically Necessary / Insufficient Evidence
Intraosseous Radiofrequency Nerve Ablation of Basivertebral Nerve - Policy statement about insufficient evidence
Policy statement
| 64400 | Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (i.e., ophthalmic, maxillary, mandibular). |
| 64405 | Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve. |
| 64408 | Injection(s), anesthetic agent(s) and/or steroid; vagus nerve. |
| 64415 | Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed. |
| 64417 | Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed. |
| 64418 | Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve. |
| 64420 | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level. |
| 64421 | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level. |
| 64425 | Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves. |
| 64430 | Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve. |
Occipital block diagnostic documentation
Document nerve distribution pain, required pain characteristics (at least two of three), dysesthesia/allodynia, and tenderness or trigger point to meet initial diagnostic criteria. Affected CPT code: 64405.
Limit on number of injections
Ensure no more than four occipital injections (including the diagnostic injection) are provided within any 12-month period. Applicable CPT codes: 64405 and 64999 (unlisted nervous system procedure as applicable).
Therapeutic block response
For therapeutic occipital blocks, document temporary relief from the prior injection (e.g., decreased numeric pain rating) and at least three months of conservative therapy including heat/rest/physical therapy (including massage), NSAIDs unless contraindicated, oral anticonvulsants or tricyclic antidepressants, and activity modification. Affected CPT code: 64405.
Sympathetic block repeat requirement for CRPS
When requesting additional sympathetic blocks beyond the first or second for CRPS, document that prior block produced an immediate positive response (e.g., improved temperature of ≥1.5°C and decreased pain) and that additional blocks are spaced at least one week apart. Affected CPT codes: 64510, 64520.
Celiac plexus neurolysis criteria
Document diagnosis of pancreatic cancer with severe visceral abdominal/back pain and inadequate analgesia or intolerable opioid side effects, and absence of somatic spread (peritoneum/diaphragm). For chronic pancreatitis, document refractory pain with a non-dilated pancreatic duct and clinical benefit from the initial block. Repeat celiac plexus block for chronic pancreatitis is medically necessary only if ≥3 months have passed since the prior injection and there was documented benefit. Affected CPT codes: 64530, 64680.
PNB during surgery
If peripheral/ganglion nerve blocks are administered as part of another surgical procedure, code per standard coding practice (examples include 64415, 64445, 64447, 64450) and do not submit them separately for prior authorization or separate payment.
Non-covered indications
Claims for nerve blocks for indications deemed not medically necessary may be denied. Examples include occipital nerve blocks for migraine or cervicogenic headaches, sympathetic nerve blocks for ischemic limb pain, and peripheral nerve blocks for prevention or treatment of headaches (including migraine).
Consult applicable NCDs/LCDs and state Medicaid provisions
Providers must review and apply all applicable Medicare NCDs, LCDs, and Medicare Coverage Articles prior to applying these criteria. For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this clinical policy.
Clinical judgment and medical necessity
This clinical policy is a guide to medical necessity and does not dictate care or guarantee payment. Providers are expected to exercise professional medical judgment in treatment decisions.
Policy adoption and effective date awareness
This clinical policy is effective as of the date determined by the Health Plan; the posting date may differ from the effective date. Legal and regulatory requirements govern if there is a discrepancy.
Guideline and systematic-review evidence supports celiac plexus neurolysis for pain related to advanced pancreatic cancer: a multidisciplinary international guideline issued a strong recommendation based on moderate-quality evidence, and a Cochrane review found significantly reduced opiate use and lower pain versus control. Repeat neurolysis for pancreatic cancer is of limited effectiveness and not routinely recommended.
For other indications the evidence is limited or conflicting. Genicular nerve blocks/neurolysis and genicular radiofrequency neurotomy have limited/conflicting evidence; small studies suggest possible benefit but further research is needed. Peripheral/ganglion nerve blocks for headache prevention/treatment (including migraine and short-lasting unilateral neuralgiform headaches) and for trigeminal neuralgia have insufficient evidence to establish effectiveness.
Intraosseous basivertebral nerve ablation (e.g., Intracept) has an FDA-approved device, but the available clinical evidence is largely industry-sponsored and of generally poor to fair quality; clinical guidelines and reviews provide only weak support and overall there is insufficient evidence to determine safety and effectiveness for vertebrogenic chronic low back pain.
| Evidence Item | Summary |
|---|---|
| Celiac plexus neurolysis - guideline support | Strong recommendation based on moderate quality evidence from a multidisciplinary international guideline for pain associated with advanced pancreatic cancer. |
| Celiac plexus neurolysis - Cochrane | 2011 Cochrane review found celiac plexus block significantly reduced opiate use and lowered pain versus control; meta-analyses report pooled pain relief in 53%–80% of patients with pancreatic cancer for EUS-guided neurolysis. |
| Genicular interventions | Limited and conflicting evidence; small studies and preliminary trials suggest possible benefit for knee pain but further research is needed to establish safety and efficacy. |
| Intracept / basivertebral ablation | FDA-approved device (Intracept) exists but evidence is mostly industry-sponsored, limited in size and poor/fair quality; insufficient evidence to determine safety and effectiveness for chronic low back pain. |
CRPS: Complex regional pain syndrome (CRPS) — also called reflex sympathetic dystrophy — is defined in this policy as CRPS (aka reflex sympathetic dystrophy).
PNB: Peripheral nerve block (PNB) — procedure involving injection(s) of local anesthetic (with or without steroid) to temporarily interrupt conduction in peripheral nerves for diagnostic or therapeutic purposes.
| Type | Number | Name | Effective Date |
|---|---|---|---|
| NCD | MC.CP.MP.170 | Peripheral Nerve Blocks and Ablation of Peripheral Nerves for Pain Management (Medicare reference) | |
| LCD | L36850 / L33933 | Peripheral nerve blocks | 2017-05-01 (L36850), 2015-10-01 (L33933) |
| LCD | L39420 | Thermal destruction of the intraosseous basivertebral nerve (BVN) for vertebrogenic lower back pain | 2023-03-05 |
| LCA | A57788 | Peripheral nerve blocks (article) | 2018-10-03 (revised 2024-10-01) |
No impact to clinical criteria — Added note directing sacroiliac and facet joint interventions to CP.MP.166 and CP.MP.171 respectively, and for Medicare plans to MC.CP.MP.170 (administrative clarification).
Administrative clarification only — Added clarifying verbiage regarding non‑Medicare health plans in Policy/Criteria with no impact to criteria.
Minor wording change to conservative therapy list for CRPS — Updated Criteria II.A.1.c to include topical application of lidocaine (non‑material wording change).
Criteria added (material) — Added refractory chronic pancreatitis as a medically necessary indication for celiac plexus block and criteria for repeat injection (>= three months and documented benefit).
Coding update (non‑material) — Added CPT code 64628 (thermal destruction of intraosseous basivertebral nerve) to referenced CPT list.
Administrative/clinical edits (non‑material) — Policy split from CP.MP.118; reworded CRPS diagnostic criteria and added requirement of positive response to first/second block for additional requests; blocks at least one week apart; expanded celiac plexus criteria for pancreatic cancer; changed ischemic leg pain to not medically necessary.
Added section VII — Insufficient evidence statement for intraosseous radiofrequency basivertebral nerve ablation (document restructuring/title change).
Annual review — Added 'as effectiveness has not been established' to occipital nerve block not medically necessary statement; background and minor wording updates.
Annual review — Minor rewording and references updated.